1 张百红,岳红云.肿瘤社会属性探究[J].医学争鸣,2012,3(6):9.
2 Shackleton M,Quintana E,Fearon ER,et al.Heterogeneity in cancer:cancer stem cells versus clonal evolution[J].Cell,2009,138(5):822-829.
3 Chen J,Li Y,Yu TS,et al.A restricted cell population propagates glioblastoma growth after chemotherapy[J].Nature,2012,488(7412):522-526.
4 Fu J,Koul D,Yao J,et al.Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells[J].Cancer Res,2013,73(10):3062-3074.
5 Zhao W,Wang L,Han H,et al.1B50-1,a mAb raised against recurrent tumor cells,targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit[J].Cancer Cell,2013,23(4):541-556.
6 Yang T,Rycaj K,Liu ZM,et al.Cancer stem cells:constantly evolving and functionally heterogeneous therapeutic targets[J].Cancer Res,2014,74(11):2922-2927.
7 Cheng L,Huang Z,Zhou W,et al.Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth[J].Cell,2013,153(1):139-152.
8 Tam WL,Lu H,Buikhuisen J,et al.Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells[J].Cancer Cell,2013,24(3):347-364.
9 Joosse SA,Pantel K.Biologic challenges in the detection of circulating tumor cells[J].Cancer Res,2013,73(1):8-11.
10 Steinert G,Schlch S,Niemietz T,et al.Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer[J].Cancer Res,2014,74(6):1694-1704.
11 Campbell PJ,Yachida S,Mudie LJ,et al.The patterns and dynamics of genomic instability in metastatic pancreatic cancer[J].Nature,2010,467(7319):1109-1113.
12 Giancotti FG.Mechanisms governing metastatic dormancy and reactivation[J].Cell,2013,155(4):750-764.
13 Hanahan D,Coussens LM.Accessories to the crime:functions of cells recruited to the tumor microenvironment[J].Cancer Cell,2012,21(3):309-322.
14 Zhang J,Liu J.Tumor stroma as targets for cancer therapy[J].Pharmacol Ther,2013,137(2):200-215.
15 de la Puente P,Muz B,Azab F,et al.Cell trafficking of endothelial progenitor cells in tumor progression[J].Clin Cancer Res,2013,19(13):3360-3368.
16 Ohsawa S,Sato Y,Enomoto M,et al.Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila[J].Nature,2012,490(7421):547-551.
17 Sohn YS,Tamir S,Song L,et al.NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth[J].PNAS,2013,110(36):14676-14681.
18 Leanza L,Zoratti M,Gulbins E,et al.Mitochondrial ion channels as oncological targets[J].Oncogene,2014,33(49):5569-5581.
19 Chae YC,Caino MC,Lisanti S,et al.Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s[J].Cancer Cell,2012,22(3):331-344.
20 Gyparaki MT,Papavassiliou AG.Lysosome:the cell′s ′suicidal bag′ as a promising cancer target[J].Trends Mol Med,2014,20(5):239-241.
21 Wang WA,Groenendyk J,Michalak M.Endoplasmic reticulum stress associated responses in cancer[J].Biochim Biophys Acta,2014,1843(10):2143-2149.
22 Mashima T,Soma-Nagae T,Migita T,et al.TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression[J].Cancer Res,2014,74(17):4888-4897.
23 Vader P,Breakefield XO,Wood MJ.Extracellular vesicles:emerging targets for cancer therapy[J].Trends Mol Med,2014,20(7):385-393.
24 EL Andaloussi S,Mger I,Breakefield XO,et al.Extracellular vesicles:biology and emerging therapeutic opportunities[J].Nat Rev Drug Discov,2013,12(5):347-357.
25 Korzeniewski N,Hohenfellner M,Duensing S.The centrosome as potential target for cancer therapy and prevention[J].Expert Opin Ther Targets,2013,17(1):43-52.
26 Hein N,Hannan KM,George AJ,et al.The nucleolus:an emerging target for cancer therapy[J].Trends Mol Med,2013,19(11):643-654.
27 张百红,岳红云.肿瘤的起源:局部或全身？[J].实用肿瘤学杂志,2013,27(5):444-446.
28 Elf SE,Chen J.Targeting glucose metabolism in patients with cancer[J].Cancer,2014,120(6):774-780.
29 Ganapathy-Kanniappan S,Geschwind JF.Tumor glycolysis as a target for cancer therapy:progress and prospects[J].Mol Cancer,2013,12:152.
30 Fang H,Declerck YA.Targeting the tumor microenvironment:from understanding pathways to effective clinical trials[J].Cancer Res,2013,73(16):4965-4977.